Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma

Exclusion Criteria

• •Patient must not have obvious clinical progression of lymphoma after PBSCT as determined by the treating physician.
• •Cannot be positive for hepatitis B surface antigen, hepatitis B core antibody or HIV antibody.
• •No major or uncontrolled comorbid conditions as determined by the treating physician: history of ventricular arrhythmias requiring drug or device therapy; uncontrolled angina or symptomatic congestive heart failure; • severe or uncontrolled infection requiring systemic antibiotic or antifungal therapy or active hepatitis C infection; severe or uncontrolled psychiatric illness.
• •No known leptomeningeal involvement by lymphoma or current metastatic brain disease.
• •No Corrected QTc interval \> 480 msec.
• •No known or suspected hypersensitivity to ofatumumab or SB-485232 that in the opinion of the investigator is a contraindication to their participation in the study.
• •No systemic (oral or parenteral) corticosteroids within 14 days of study entry.
• •Not receiving concurrent chemotherapy, biologic therapy, radiotherapy, or other investigational therapy.
• •No previous treatment with SB-485232 or ofatumumab.
• •No history of other malignancy except for adequately treated non-invasive cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
• •No diabetes mellitus with poor glycemic control (documented hemoglobin A1c \>7% within 4 weeks prior to study entry).